Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Obsv save search
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: 0.0%
yselty treatment authorization
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-06-17 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: -1.09%
H: 4.95%
C: -1.1%
yselty treatment authorization
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
Published: 2022-05-09 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 7.1%
H: 1.66%
C: -18.78%
treatment linzagolix
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-04-25 (Crawled : 06:00) - globenewswire.com
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: -8.39%
H: 1.73%
C: 0.48%
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 4.29%
H: 9.59%
C: 8.22%
treatment chmp positive
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-02-04 (Crawled : 00:20) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
treatment uterine fibroids linzagolix
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2021-12-17 (Crawled : 13:30) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
treatment uterine fibroids positive linzagolix chmp
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
Published: 2021-10-20 (Crawled : 09:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -1.82%
treatment uterine fibroids linzagolix
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
Published: 2021-09-15 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 3.32%
H: 0.96%
C: -1.61%
new drug treatment fda drug submission linzagolix application
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
Published: 2021-07-27 (Crawled : 05:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 19.84%
H: 18.54%
C: -4.97%
treatment license commercialization
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
Published: 2021-06-30 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 1.66%
H: 0.65%
C: -0.98%
treatment ev linzagolix
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
Published: 2021-06-10 (Crawled : 06:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 2.65%
H: 4.19%
C: 1.61%
treatment phase 2 phase 2b
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
Published: 2021-05-20 (Crawled : 07:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 8.83%
H: 0.0%
C: -5.52%
treatment results phase 3 linzagolix
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Published: 2020-12-10 (Crawled : 06:01) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 7.18%
H: 5.36%
C: 5.36%
results phase 3 treatment linzagolix
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.